← Back to Search

Endoscopy

Tethered Capsule Endomicroscopy for Barrett's Esophagus

N/A
Waitlist Available
Led By Guillermo Tearney, M.D, PhD.
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up imaging data is collected during the procedure, and analyzed within 1 year of collection.
Awards & highlights

Study Summary

This trial is testing whether a new screening method for Barrett's Esophagus is feasible in a primary care clinic environment, as well as determining the prevalence of Barrett's Esophagus in patients seen at MGH.

Who is the study for?
This trial is for adults aged 18-75 who are patients at the Assembly Row primary care practice, can consent to participate, and haven't eaten for an hour before the procedure. It's not for pregnant individuals, those with swallowing difficulties, urgent symptoms like fever or abdominal pain, a history of certain GI surgeries or Crohn's disease.Check my eligibility
What is being tested?
The study is testing tethered capsule endomicroscopy as a way to screen for Barrett's Esophagus in a regular doctor’s office setting. The goal is to see if this method works well in primary care and how common Barrett's Esophagus is among these patients.See study design
What are the potential side effects?
Since this trial involves a non-invasive imaging technique rather than medication, side effects may be minimal but could include discomfort during the procedure or minor throat irritation afterwards.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~imaging data is collected during the procedure, and analyzed within 1 year of collection.
This trial's timeline: 3 weeks for screening, Varies for treatment, and imaging data is collected during the procedure, and analyzed within 1 year of collection. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Prevalence of Barrett's esophagus within the single Primary Care Practice cohort.
Subject Tolerability of Tethered Capsule Endomicroscopy Swallow

Trial Design

1Treatment groups
Experimental Treatment
Group I: Feasibility of TCE & Prevalence of BEExperimental Treatment1 Intervention
Feasibility of using tethered capsule endomicroscopy as a screening method for Barrett's esophagus in the primary care practice environment Determine the prevalence of Barrett's esophagus in a primary care practice cohort at MGH

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,918 Previous Clinical Trials
13,192,635 Total Patients Enrolled
Guillermo Tearney, M.D, PhD.Principal InvestigatorMassachusetts General Hospital
6 Previous Clinical Trials
440 Total Patients Enrolled

Media Library

Tethered Capsule Endomicroscopy (Endoscopy) Clinical Trial Eligibility Overview. Trial Name: NCT04561791 — N/A
Barrett's Esophagus Research Study Groups: Feasibility of TCE & Prevalence of BE
Barrett's Esophagus Clinical Trial 2023: Tethered Capsule Endomicroscopy Highlights & Side Effects. Trial Name: NCT04561791 — N/A
Tethered Capsule Endomicroscopy (Endoscopy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04561791 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is access to this research endeavor currently available for participants?

"Clinicaltrials.gov confirms that this medical trial is no longer accepting new participants, though it was initially posted on the 2nd of January 2019 and last updated on September 22nd 2020. Nonetheless, there are 36 other clinical trials actively searching for patients right now."

Answered by AI
~25 spots leftby Dec 2024